Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.

Yue-Yun ChenPei-Pei WangYang HuYong YuanYu-Shang YangHua-Shan ShiQing HaoZhen LinJiang-Fang TianYue ZhengTing LiuPan-Pan LinHeng Xu Xue-Lei Ma Li YangZhen-Yu Ding

Published in: British journal of cancer (2024)

Neoadjuvant camrelizumab plus chemotherapy is effective for locally advanced, resectable ESCC, eliciting profound immune response that closely associated with clinical outcomes.

Keyphrases

locally advanced
immune response
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
phase ii study
radiation therapy
dendritic cells
toll like receptor
lymph node metastasis
intellectual disability
autism spectrum disorder